Aquestive Therapeutics, Inc. (AQST)
USD 2.52
(2.02%)
USD 2.52
(2.02%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 44.85 Million USD | -36.25% |
| 2022 | 70.36 Million USD | -0.23% |
| 2021 | 70.52 Million USD | -6.94% |
| 2020 | 75.77 Million USD | -10.76% |
| 2019 | 84.91 Million USD | -10.97% |
| 2018 | 95.37 Million USD | 102.02% |
| 2017 | 47.21 Million USD | 30.22% |
| 2016 | 36.25 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 15.51 Million USD | -6.64% |
| 2024 Q1 | 16.62 Million USD | 33.63% |
| 2024 Q3 | 17.39 Million USD | 12.1% |
| 2023 Q2 | 10.83 Million USD | -1.54% |
| 2023 Q1 | 11 Million USD | -31.62% |
| 2023 FY | 44.85 Million USD | -36.25% |
| 2023 Q4 | 12.43 Million USD | 17.55% |
| 2023 Q3 | 10.58 Million USD | -2.33% |
| 2022 FY | 70.36 Million USD | -0.23% |
| 2022 Q1 | 17.79 Million USD | -8.19% |
| 2022 Q4 | 16.09 Million USD | 2.54% |
| 2022 Q3 | 15.69 Million USD | -24.51% |
| 2022 Q2 | 20.78 Million USD | 16.81% |
| 2021 FY | 70.52 Million USD | -6.94% |
| 2021 Q1 | 16.89 Million USD | -15.58% |
| 2021 Q2 | 17.39 Million USD | 3.0% |
| 2021 Q3 | 16.85 Million USD | -3.11% |
| 2021 Q4 | 19.38 Million USD | 14.99% |
| 2020 Q4 | 20 Million USD | 4.95% |
| 2020 Q2 | 17.74 Million USD | -6.46% |
| 2020 FY | 75.77 Million USD | -10.76% |
| 2020 Q1 | 18.96 Million USD | -2.89% |
| 2020 Q3 | 19.06 Million USD | 7.45% |
| 2019 Q2 | 24.39 Million USD | 9.84% |
| 2019 FY | 84.91 Million USD | -10.97% |
| 2019 Q4 | 19.53 Million USD | 4.02% |
| 2019 Q3 | 18.77 Million USD | -23.04% |
| 2019 Q1 | 22.21 Million USD | -8.92% |
| 2018 Q2 | 41.64 Million USD | 233.93% |
| 2018 FY | 95.37 Million USD | 102.02% |
| 2018 Q4 | 24.38 Million USD | 44.48% |
| 2018 Q3 | 16.87 Million USD | -59.47% |
| 2018 Q1 | 12.47 Million USD | -9.87% |
| 2017 Q2 | 10.06 Million USD | -12.3% |
| 2017 Q3 | 11.84 Million USD | 17.74% |
| 2017 Q1 | 11.47 Million USD | 0.0% |
| 2017 Q4 | 13.83 Million USD | 16.81% |
| 2017 FY | 47.21 Million USD | 30.22% |
| 2016 FY | 36.25 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 71.827% |
| Embecta Corp. | 528.4 Million USD | 91.511% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 77.113% |
| Dynavax Technologies Corporation | 219.14 Million USD | 79.532% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 83.503% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 86.257% |
| PainReform Ltd. | 9.58 Million USD | -368.009% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -241.759% |
| SCYNEXIS, Inc. | 51.84 Million USD | 13.489% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1361.429% |
| Cosmos Health Inc. | 26.18 Million USD | -71.324% |
| Journey Medical Corporation | 54.59 Million USD | 17.841% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -241.759% |
| Safety Shot Inc | 12.1 Million USD | -270.397% |
| Alpha Teknova, Inc. | 45.85 Million USD | 2.192% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 92.398% |
| Bright Green Corporation | 8.25 Million USD | -443.496% |
| Procaps Group, S.A. | 199.47 Million USD | 77.514% |
| Theratechnologies Inc. | 72.75 Million USD | 38.35% |
| Harrow Health, Inc. | 89.97 Million USD | 50.147% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -374.846% |
| Biofrontera Inc. | 39.95 Million USD | -12.25% |
| DURECT Corporation | 43.71 Million USD | -2.606% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 91.521% |
| Cronos Group Inc. | 96.7 Million USD | 53.62% |
| OptiNose, Inc. | 85.1 Million USD | 47.294% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 80.677% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -14.561% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 569.135% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 85.721% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -360.947% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -4.213% |
| Radius Health, Inc. | 265.92 Million USD | 83.133% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -224.045% |
| ProPhase Labs, Inc. | 37.85 Million USD | -18.498% |
| Phibro Animal Health Corporation | 260.29 Million USD | 82.768% |
| Procaps Group S.A. | 187.24 Million USD | 76.045% |
| Alvotech | 285.43 Million USD | 84.286% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -356.529% |
| Viatris Inc. | 5.96 Billion USD | 99.248% |
| Rockwell Medical, Inc. | 15.37 Million USD | -191.752% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 25.043% |
| SIGA Technologies, Inc. | 22.04 Million USD | -103.484% |
| Tilray Brands, Inc. | 251.35 Million USD | 82.155% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 8.532% |
| Shineco, Inc. | 17.94 Million USD | -149.91% |
| PetIQ, Inc. | 192.72 Million USD | 76.726% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -1023.84% |
| Incannex Healthcare Limited | 30.05 Million USD | -49.25% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 97.19% |
| Alimera Sciences, Inc. | 62.64 Million USD | 28.395% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -5782.554% |
| Assertio Holdings, Inc. | 368.58 Million USD | 87.831% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -662.101% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -151.868% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -111.885% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -113.163% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 72.81% |
| Hempacco Co., Inc. | 7.59 Million USD | -490.46% |
| Talphera, Inc. | 11.99 Million USD | -273.97% |
| Alvotech | 285.43 Million USD | 84.286% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 68.124% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 86.995% |
| Currenc Group, Inc. | 24 Million USD | -86.875% |
| Kamada Ltd. | 45.42 Million USD | 1.259% |
| Indivior PLC | 911 Million USD | 95.076% |
| Evoke Pharma, Inc. | 12.4 Million USD | -261.445% |
| Flora Growth Corp. | 10.57 Million USD | -323.991% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -113.163% |
| Evolus, Inc. | 189.75 Million USD | 76.363% |
| HUTCHMED (China) Limited | 436.23 Million USD | 89.718% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 70.899% |
| Akanda Corp. | 3.48 Million USD | -1187.61% |